Telmaheal

📦 Κάθε παραγγελία καλύπτεται από την Πολιτική Εγγύησης Επαναποστολής — εάν το δέμα σας δεν φτάσει εντός 20 εργάσιμων ημερών, το επαναποστέλλουμε.

Γιατί να παραγγείλετε από τη MedsBase

Τα γενόσημα φάρμακά μας προέρχονται από κατασκευαστές που πιστοποιούνται από την WHO-GMP και αποστέλλονται παγκοσμίως σε διακριτική, απλή συσκευασία — χωρίς όνομα φαρμάκου στο εξωτερικό του δέματος. Οι πληρωμές με κάρτα δρομολογούνται μέσω ρυθμισμένου επεξεργαστή (οι περιγραφές εκκαθάρισης περιλαμβάνουν ρυθμισμένο επεξεργαστή πληρωμών με κάρτα — ποτέ “MedsBase” ή οποιοδήποτε όνομα φαρμάκου). Γίνονται δεκτές και πληρωμές με κρυπτονομίσματα και τραπεζική μεταφορά SEPA. Κάθε παραγγελία καλύπτεται από την Πολιτική Επαναποστολής Εξασφαλίσεώς μας.

What Is Telmaheal?

Telmaheal is an oral 20 / 40 / 80 mg telmisartan tablet from a WHO-GMP certified manufacturer, supplied in 30-180 tablets. Introduced 1998 (Boehringer Ingelheim as Micardis). Distinguished by the longest half-life of any ARB (24 hours) and additional partial PPAR-γ agonist activity. Active drug (not a prodrug); no metabolic activation required. Half-life 24 hours — gives the smoothest 24-hour BP profile of any ARB and often controls early-morning BP better than shorter-acting agents.

How Telmisartan Lowers Blood Pressure

ARBs block the angiotensin II type 1 (AT₁) receptor directly, preventing angiotensin II from binding and exerting its vasoconstrictor and aldosterone-releasing effects. This is one receptor downstream of where ACE inhibitors act (which block angiotensin II formation) and produces equivalent clinical effects:

• Direct arterial vasodilation — lower systemic vascular resistance = lower blood pressure
• Reduced aldosterone secretion — less sodium and water retention
• Reduced sympathetic nervous system activation
• Improved endothelial function and reduced ventricular remodelling — the vascular-protective mechanism beyond simple BP lowering
• NO bradykinin accumulation — this is the key clinical difference from ACE inhibitors. ARBs do NOT cause the dry cough that affects up to 20% of ACEi users, because they don’t interfere with bradykinin metabolism.

Clinical consequence of this mechanism: ARBs achieve equivalent BP control to ACE inhibitors with lower rates of cough (0-3% vs 20% for ACEi) and angioedema (roughly 30-50% lower than ACEi, though not zero).

Approved and Evidence-Based Uses

• Hypertension — primary indication; first-line per international guidelines
• Hypertension with metabolic syndrome, type 2 diabetes, or impaired glucose tolerance — PPAR-γ metabolic benefit
• Cardiovascular risk reduction in patients with established vascular disease or diabetes + risk factor — ONTARGET-approved
• Hypertension where smooth 24-hour control matters (early-morning BP surge, white-coat hypertension, circadian ambulatory BP targets)
• Intolerance to ACE inhibitors (cough, less commonly angioedema) — standard switch target

Pivotal trial evidence: ONTARGET (2008) — telmisartan 80 mg non-inferior to ramipril 10 mg for cardiovascular outcomes in high-risk patients; combination worse than either alone. TRANSCEND — telmisartan in ACEi-intolerant patients. ONTARGET is the main trial demonstrating ARB/ACEi equivalence for vascular protection outside hypertension.

Telmaheal Dosage

Hypertension:

• Starting dose: 40 mg once daily (20 mg if elderly, hepatic impaired, or in combination with diuretic)
• Target dose: 40-80 mg once daily
• Maximum: 80 mg once daily
• Titrate every 2-4 weeks; full antihypertensive effect at 3-6 weeks

Heart failure: 80 mg once daily; less HF evidence than valsartan/candesartan but non-inferior to ramipril in ONTARGET

Administration: once daily, with or without food. Take at the same time each day for stable BP control.

Παρακολούθηση:

• Baseline: urea, electrolytes (particularly potassium), creatinine, eGFR. Home BP baseline.
• After 1-2 weeks: repeat U&E. Small rise in creatinine (up to 30%) is expected and acceptable. Small rise in potassium is common.
• After dose increase: repeat U&E at 1-2 weeks.
• Ongoing: annual U&E once stable.
• Stop and investigate: creatinine rise >30%, eGFR fall >25%, potassium >5.5, symptomatic hypotension.

Discontinuation: no withdrawal syndrome; however, abrupt stop causes BP rebound over days. Taper over 1-2 weeks when stopping.

Παρενέργειες

Common (>1%, usually mild):

• Dizziness, postural hypotension (usually mild; more common at start of therapy)
• Mild hyperkalaemia
• Expected small creatinine rise (up to ~30% is acceptable; intrarenal haemodynamic change, not nephrotoxicity)
• Fatigue, headache
• Upper respiratory symptoms, nasopharyngitis
• Back pain, muscle cramps

Uncommon but important:

• Angioedema — lower rate than with ACE inhibitors but still possible. Incidence ~0.1%. Do NOT use an ARB if the patient has a documented history of angioedema to an ACE inhibitor in the first 4 weeks; longer-term cautious use often acceptable.
• Severe hyperkalaemia — particularly with potassium-sparing diuretics (spironolactone), potassium supplements, NSAIDs, or CKD
• Acute kidney injury in bilateral renal artery stenosis — same mechanism as ACE inhibitors
• First-dose hypotension in volume-depleted patients (e.g. on high-dose diuretics, severe HF)

Αντενδείξεις

• Pregnancy — ABSOLUTE contraindication at all trimesters. Same teratogenic profile as ACE inhibitors. Stop immediately on pregnancy; switch to labetalol, methyldopa, nifedipine, or hydralazine.
• History of angioedema with any ACE inhibitor or ARB (within 4 weeks)
• Bilateral renal artery stenosis or stenosis in a single functioning kidney
• Severe hepatic impairment (Child-Pugh C) — particularly for prodrug ARBs
• Hyperkalaemia >5.5 mmol/L at baseline
• Concurrent use of sacubitril/valsartan (Entresto) — 36-hour washout required when switching
• Concurrent aliskiren in diabetes or CKD (ALTITUDE trial harm)
• Concurrent ACE inhibitor — ONTARGET trial harm without benefit
• Hypersensitivity to telmisartan

Breastfeeding: avoid in the first weeks after delivery of a premature infant. Long-term use in established breastfeeding is generally considered acceptable given low milk transfer, but alternative antihypertensives (propranolol, nifedipine) are preferred when possible.

Αλληλεπιδράσεις Φαρμάκων

• Potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene) — additive hyperkalaemia; monitor closely
• Potassium supplements and salt substitutes — hyperkalaemia risk
• Μη στεροειδή αντιφλεγμονώδη φάρμακα (NSAIDs) — reduce antihypertensive effect and increase AKI risk (particularly the “triple whammy”: ARB + diuretic + NSAID)
• Lithium — ARBs reduce lithium clearance; monitor levels
• Αναστολείς ACE — do NOT combine (ONTARGET harm)
• Sacubitril/valsartan (Entresto) — do not combine; 36-hour washout
• Aliskiren — avoid in diabetes or CKD (ALTITUDE harm)

ARB Class at a Glance

ARB vs ACE Inhibitor — When to Choose an ARB

ACE inhibitors (ramipril, enalapril, lisinopril, perindopril) and ARBs act on the same renin-angiotensin pathway and produce equivalent BP-lowering and cardiovascular protection. Choose an ARB when:

• ACE-inhibitor cough has appeared (up to 20% of users; most common reason for switch)
• Past ACE-inhibitor angioedema (use an ARB cautiously, not within 4 weeks of the angioedema episode)
• Some patients prefer the once-daily profile of long-acting ARBs like telmisartan for smooth 24-hour control
• Specific molecule indications — losartan for HTN+gout, irbesartan for type 2 diabetic nephropathy, valsartan as a precursor to ARNI in HF

Do NOT combine ARB + ACE inhibitor. ONTARGET trial (2008) showed the combination produces MORE adverse events (hyperkalaemia, AKI, hypotension) without any additional cardiovascular benefit. If a patient is on both, stop one.

Αποθήκευση

Store Telmaheal below 25°C in the original blister pack. Keep out of reach of children.

Συχνές Ερωτήσεις

How long does Telmaheal take to lower blood pressure?

Initial BP drop within 1-2 hours; full antihypertensive effect at 3-6 weeks. Measure home BP at the same time each day to track response. If BP has not come to target at 6 weeks, either increase dose or add a second-class agent (CCB or thiazide are the standard add-ons to an ARB).

I switched from an ACE inhibitor because of cough — will my cough go away?

Yes. The ACE-inhibitor cough is caused by bradykinin accumulation; ARBs do not raise bradykinin. The cough typically resolves within 1-4 weeks of stopping the ACE inhibitor. If your cough persists beyond 6 weeks after switching to Telmaheal, investigate an alternative cause (reflux, postnasal drip, asthma).

Can I take Telmaheal in pregnancy?

No — ARBs are absolutely contraindicated in pregnancy, same as ACE inhibitors. They cause fetal renal agenesis, oligohydramnios, pulmonary hypoplasia, and skull defects. Stop immediately if pregnancy occurs. Women of childbearing potential should use reliable contraception; for those planning pregnancy, switch to labetalol, methyldopa, or nifedipine pre-conception.

My creatinine went up a bit after starting Telmaheal — should I stop?

A creatinine rise of up to 30% within the first 1-2 weeks is expected and acceptable. It reflects normal intrarenal haemodynamic adjustment as angiotensin-II-mediated efferent arteriolar tone is removed. A rise >30% suggests bilateral renal artery stenosis, volume depletion, or NSAID interaction and requires investigation (stop the drug, get renal imaging, review concurrent medication).

Should I avoid potassium-rich foods on Telmaheal?

Moderate intake of potassium-rich foods (bananas, oranges, spinach, avocado, potatoes) is fine for most users. Avoid potassium supplements (slow-K) and potassium-containing salt substitutes unless specifically prescribed — these can cause dangerous hyperkalaemia when combined with ARBs, particularly in CKD or with potassium-sparing diuretics.

Can I combine Telmaheal with my other BP medications?

Yes — ARBs combine well with calcium-channel blockers (amlodipine), thiazide diuretics (HCTZ), and beta-blockers (bisoprolol, metoprolol succinate). Do NOT combine an ARB with an ACE inhibitor (ramipril, lisinopril, etc.) — ONTARGET trial showed harm without benefit.

Can I take ibuprofen with Telmaheal?

Occasional short-term use is usually acceptable; chronic daily NSAIDs (ibuprofen, diclofenac, naproxen) reduce the antihypertensive effect of ARBs AND substantially raise the AKI risk — particularly when combined with a diuretic (the “triple whammy”). For chronic pain, paracetamol is safer; for inflammation, discuss alternatives.

Is Telmaheal lifelong?

For most patients with essential hypertension, yes — antihypertensive therapy is lifelong because stopping returns BP to pre-treatment levels within days to weeks. Some patients lose their hypertension through significant weight loss, reduced alcohol intake, or better sleep; their physician may then trial a careful taper under BP monitoring. Never stop Telmaheal without medical advice.

Τι γίνεται αν χάσω μια δόση;

Take the missed dose as soon as you remember, unless it is nearly time for the next dose — in that case skip the missed dose and continue your normal schedule. Do not double up. A single missed dose will not meaningfully affect long-term BP control.

Where can I buy Telmaheal online?

You can buy Telmaheal (telmisartan 20 / 40 / 80 mg, 30-180 tablets) from MedsBase with discreet packaging and worldwide shipping.

Related Antihypertensives on MedsBase

• Amlode — Amlodipine CCB
• Cosart — Losartan 25 mg
• Cosart-H — Losartan + HCTZ
• Cozartan-H — Losartan + HCTZ
• Lispro — Lisinopril (ACEi alternative)
• Targit — Telmisartan 80 mg
• Browse all High Blood Pressure Medications

Σχετικές Εναλλακτικές

Άλλα προϊόντα σε Χρόνιες Παθήσεις που οι πελάτες εξετάζουν επίσης:

• Predniheal
• Donemax
• Temotero
• Aricep
• Jardiance (Empagliflozin)

Περισσότερες επιλογές σε φάρμακα για υψηλή πίεση αίματος

Ταξινομημένα σύμφωνα με τον όγκο παραγγελιών στο MedsBase — τι επιλέγουν άλλοι πελάτες σε αυτήν την κατηγορία.

Losar

US$6.53 – US$29.25Preisspanne: US$6.53 bis US$29.25

Amlode

US$5.50 – US$24.00Preisspanne: US$5.50 bis US$24.00

Minoxytop

US$22.00 – US$170.00Preisspanne: US$22.00 bis US$170.00

Rosuline

US$18.00 – US$117.00Preisspanne: US$18.00 bis US$117.00